Turing Pharmaceuticals, the company that elicited public outcry after raising the price of its drug Daraprim by 5,000 percent overnight, faces an antitrust inquiry regarding its marketing and distribution of the drug, according to a report from JD Supra.
Martin Shkreli, the 32-year-old CEO of Turing Pharmaceuticals, headed the company’s purchase of Daraprim in August from Impax Laboratories for $55 million. Daraprim is an antiparasite medication developed 62 years ago.
In September, he increased the price of the drug from $13.50 to $750 per pill overnight, a decision that precipitated public backlash. Ultimately, Mr. Shkreli backed down and said he would lower the price of the drug to an undisclosed amount, according to the report.
However, Turing’s original announcement and subsequent public scrutiny captured the attention of the New York Attorney General’s office. According to the report, the antitrust chief under Attorney General Eric Schneiderman sent Mr. Shkreli and Turing a letter requesting he contact the Attorney General’s office to discuss the company’s distribution channel.
Full content: JD Supra
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
SEC Sues Elon Musk Over Delayed Disclosure of Twitter Stock Ownership
Jan 15, 2025 by
CPI
European Commission Orders Lufthansa to Support Condor’s Frankfurt-New York Route
Jan 15, 2025 by
CPI
No Pause for Big Tech Probes: EU Keeps Pressure on as Trump Arrives
Jan 15, 2025 by
CPI
Meta Faces Roadblocks in India After Antitrust Ruling, Warns of Feature Rollbacks
Jan 15, 2025 by
CPI
Massachusetts AG Sues Insulin Makers and PBMs Over Alleged Price-Fixing Scheme
Jan 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand